Belen Morenes - Grifols SA Independent Director
| GIFOF Stock | USD 6.87 0.00 0.00% |
Director
Ms. Belen Villalonga Morenes serves as Director of Grifols, S.A. since 2018. She is an Associate Professor with Tenure at New York University Stern School of Business. Between 2001 and 2012, she was a faculty member at Harvard Business School. She serves as an independent director at Acciona, leader in the renewable energy and infrastructure businesses, since 2006, and at Talgo, a highspeed train manufacturer, since 2015. She is also a Senior Associate Partner at Cambridge Advisors to Family Enterprise, a family business consulting company. Her teaching, research, and consulting activities are in the areas of corporate strategy, finance, and governance, with a special focus on familycontrolled companies. Her awardwinning research, which was published in the top academic journals, was cited extensively in academic articles and in the international media. She holds a Bachelors degree in Economics from Universidad Complutense de Madrid, Doctorate in Philosophy degree in Business Science from Universidad Complutense de Madrid, Masters degree in Economics from University of California, Los Angeles, Doctorate in Philosophy degree in Economics from Universidad Complutense de Madrid and Doctorate in Philosophy in Business Administration from University of California, Los Angeles. since 2018.
| Age | 45 |
| Tenure | 6 years |
| Phone | 34 93 571 02 21 |
| Web | https://www.grifols.com |
Grifols SA Management Efficiency
The company has return on total asset (ROA) of 0.0155 % which means that it generated a profit of $0.0155 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0182 %, meaning that it generated $0.0182 on every $100 dollars invested by stockholders. Grifols SA's management efficiency ratios could be used to measure how well Grifols SA manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| JeanPhilippe Courtois | AstraZeneca PLC ADR | 54 | |
| Carole Piwnica | Sanofi ADR | 60 | |
| Per WoldOlsen | Gilead Sciences | 70 | |
| Deborah DiSanzo | AstraZeneca PLC ADR | 59 | |
| Rudolph Markham | AstraZeneca PLC ADR | 72 | |
| Shriti Vadera | AstraZeneca PLC ADR | 55 | |
| Theodore Samuels | Bristol Myers Squibb | 66 | |
| Diane Souza | Sanofi ADR | 65 | |
| Vicki Sato | Bristol Myers Squibb | 71 | |
| SuetFern Lee | Sanofi ADR | 59 | |
| Manuel Medina | Bristol Myers Squibb | 53 | |
| Lewis Campbell | Bristol Myers Squibb | 68 | |
| Ton Buechner | Novartis AG ADR | 55 | |
| Peter Arduini | Bristol Myers Squibb | 56 | |
| Matthew Emmens | Bristol Myers Squibb | 68 | |
| Alan Lacy | Bristol Myers Squibb | 64 | |
| Julia Haller | Bristol Myers Squibb | 66 | |
| Suet Lee | Sanofi ADR | 60 | |
| Carla Hills | Gilead Sciences | 80 | |
| Claudie Haignere | Sanofi ADR | 60 | |
| Uwe Bicker | Sanofi ADR | 69 | |
Management Performance
| Return On Equity | 0.0182 | |||
| Return On Asset | 0.0155 |
Grifols SA Leadership Team
Elected by the shareholders, the Grifols SA's board of directors comprises two types of representatives: Grifols SA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Grifols. The board's role is to monitor Grifols SA's management team and ensure that shareholders' interests are well served. Grifols SA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Grifols SA's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Antonio Pares, Director of Planning and Control | ||
| Peter Allen, Chairman of Hospital OPS Division | ||
| Carsten Schroeder, President Of The Diagnostic Division | ||
| Albert Roura, CEO of Laboratorios Grifols SA | ||
| Jose Garcia, Director General De Laboratorios Grifols | ||
| Lafmin Morgan, President Of The Bioscience And Hospital Division | ||
| Juan Roura, Vice President of Production, Executive Director | ||
| Eva Tubau, Chief Scientific Officer | ||
| Anna Lluch, Independent Director | ||
| Carlos Fernandez, Deputy Industrial Vice President | ||
| Jose Gras, Director, Representative of Thorthol Holdings BV | ||
| Maria Llano, Chief Officer | ||
| Edgar Jannotta, Independent Director | ||
| Vicente Torre, CTO | ||
| Mateo Humbert, Director of Human Resources | ||
| Montserrat Calvo, Chief Administrative Officer, Controller | ||
| Montserrat Llamas, Chief Officer | ||
| Ramon Roca, Vice-President of Marketing and Sales and Executive Director | ||
| Vctor Deu, CoCEO Director | ||
| David Bell, Vice President of Corporate Operations and Development of Grifols Inc and United States Subsidiaries | ||
| Victor Deu, Co-CEO, Executive Director | ||
| Luis Bobadilla, Independent Director | ||
| Inigo Mardones, Director | ||
| Thomas Glanzmann, Director | ||
| Carina Lazaro, Independent Director | ||
| Joel Abelson, President of North America Commercial Division of Grifols Inc | ||
| Steven Mayer, Director | ||
| Jose Fulla, CEO of Diagnostic Industrial Group | ||
| Javier Ribes, CEO of Instituto Grifols SA | ||
| Alfredo Guerra, CFO and Corporate VP | ||
| Raimon Roura, Non-Member Secretary of the Board | ||
| Miguel Montblanch, Chariman of Global Operations Network | ||
| Victor Roura, Chairman, CEO and President and Member of Appointments and Remuneration Committee | ||
| Brett Ingersoll, Director | ||
| Shinji Wada, President of Plasma Centers of Grifols Inc | ||
| Tomas Gelabert, Director | ||
| Nuria Lapea, Risk Treasury | ||
| M Tubau, Co Affairs | ||
| Steven JD, Ex Chairman | ||
| Marla Salmon, Independent Director | ||
| Nuria Barnes, Non-Member Assistant Secretary of the Board | ||
| Gregory Rich, President of Grifols Inc and Subsidiaries in the US | ||
| Belen Morenes, Independent Director | ||
| Nuria Lapena, Director of Shareholder and Investor Relations |
Grifols Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Grifols SA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0182 | |||
| Return On Asset | 0.0155 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | 0.09 % | |||
| Current Valuation | 16.07 B | |||
| Shares Outstanding | 256.72 M | |||
| Shares Owned By Institutions | 25.47 % | |||
| Price To Earning | 6.10 X | |||
| Price To Book | 0.80 X | |||
| Price To Sales | 1.34 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Grifols SA. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Complementary Tools for Grifols Pink Sheet analysis
When running Grifols SA's price analysis, check to measure Grifols SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Grifols SA is operating at the current time. Most of Grifols SA's value examination focuses on studying past and present price action to predict the probability of Grifols SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Grifols SA's price. Additionally, you may evaluate how the addition of Grifols SA to your portfolios can decrease your overall portfolio volatility.
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |